Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2008

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition.

There are today more than 380 protein kinase inhibitors for the treatment of cancer, from early preclinical to marketed drugs. Protein Kinase Inhibitors in Oncology: Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 139 different targets. These targets are further categorized on the CD-ROM by 36 classifications of molecular function and with pathway referals to BioCarta, KEGG and NetPath. Read more below on how the Protein Kinase Inhibitors in Oncology: Drug Pipeline Update is organized.

How May Drug Pipeline Update Be of Use?

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

* Find competitors, collaborations partners, M&A candidates etc.

* Jump start competitive drug intelligence operations

* Excellent starting point for world wide benchmarking

* Compare portfolio and therapy focus with your peers

* Speed up pro-active in-/out licensing strategy work

* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.

Drug Pipeline Update is delivered to you as a CD-ROM application, which requires no installation on your computer. Please read more about application features and system requirements - hit more..

May 2008
More...
Price: $2,350.00 / GBP1,175.00